| Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2009 ... - MarketWatch (press release) |
|
|
MarketWatch (press release)The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is ... read more |